What is the proportion of pomalidomide reimbursed by medical insurance?

Pomalidomide (Pomalidomide) is an oral immunomodulatory drug, mainly used to treat multiple myeloma (MM) and other diseases. It fights cancer cells through immune regulation and tumor growth inhibition. The original drug of pomalidomide is not marketed in China, but a domestic version has been approved and successfully included in medical insurance. However, due to its high price, many patients still have to bear considerable costs after medical insurance reimburses them.

1. Domestic medical insurance policy

Pomalidomide is an effective drug for the treatment of multiple myeloma, and its medical insurance reimbursement policy is still in the development stage in China. At present, domestic pomalidomide has been successfully included in medical insurance, but its price is still relatively high. Therefore, even if it is reimbursed by medical insurance, the patient's out-of-pocket expense is still high. The specific reimbursement ratio and cost will vary depending on local hospitals and medical policies. Patients usually need to ask the hospital pharmacy for detailed information when visiting the hospital.

Reimbursement of pomalidomide by medical insurance mainly applies to patients with multiple myeloma who have received at least two previous treatments, including treatment with lenalidomide (Lenalidomide) and a proteasome inhibitor. Patients are only eligible for medical insurance reimbursement if their disease progresses after the last treatment or during treatment and if they meet other conditions.

2. Price and availability

The price of pomalidomide is relatively high, so many patients are troubled by the high cost of treatment. Although the price of the domestic version of pomalidomide has decreased, the cost of treatment is still a significant burden for most patients. It should be noted that the proportion of medical insurance reimbursement is not uniform and depends on the medical insurance policy in the region where the patient is located. Some areas have higher reimbursement rates, while others may still require patients to bear more costs. Therefore, patients should communicate with their local hospital to obtain more accurate cost information.

Keyword tags: Pomalidomide,Pomalidomide, medical insurance reimbursement, multiple myeloma, domestic drugs, treatment costs, medical insurance policy, patient's own expenses

Reference materials:https://go.drugbank.com/drugs/DB08910